Last reviewed · How we verify
NCT06763835: NBPE-ACS
Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis
trial testing Blood is drawn to test for specific biomarkers in Plaque Rupture in 301 participants. Participants enrolled and being followed up; not accepting new ones.
30 July 2024
Quick facts
| Lead sponsor | Xuebo Liu |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 301 |
| Start date | 1 February 2023 |
| Primary completion | 30 July 2024 |
| Estimated completion | 30 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Blood is drawn to test for specific biomarkers
Conditions studied
- Plaque Rupture — all drugs for Plaque Rupture →
- Acute Coronary Syndromes — all drugs for Acute Coronary Syndromes →
Sponsor
Xuebo Liu
Who can join
Adults 18 to 85, any sex, with Plaque Rupture or Acute Coronary Syndromes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is • Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06763835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06763835 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xuebo Liu
- Last refreshed: 14 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing